ATEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alphatec Holdings Inc (ATEC) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown growth in revenue and has a compelling valuation compared to peers, the recent Q1 earnings miss, downgraded revenue outlook, and ongoing investigation into potential securities law violations present significant risks. Additionally, there are no strong trading signals or recent influential insider or congressional trades to support a buy decision. It is advisable to monitor the stock for further developments before making an investment.
The MACD histogram is positive at 0.167, indicating bullish momentum. RSI is at 75.392, suggesting the stock is nearing overbought territory. Moving averages are converging, showing no clear trend. Key resistance levels are at 8.684 and 8.912, with support at 7.942 and 7.714. The stock closed at 8.795, slightly below the R2 resistance level.
Hedge funds are increasing their positions significantly, with a 316.57% increase in buying activity over the last quarter. The company reported a 25% revenue increase for FY 2025, indicating strong market acceptance in spine surgery. Valuation metrics such as forward P/E of 25.8x and P/S ratio of 1.7x are relatively attractive compared to peers.
Q1 2026 earnings missed expectations, and the management lowered sales guidance due to EOS weakness and unfavorable surgical case mix. Analysts have significantly reduced price targets, and the stock is under investigation for potential securities law violations. Competition from major players like Medtronic and Johnson & Johnson adds pressure.
Alphatec reported a 25% revenue increase to $764.2 million for FY 2025, but the company posted a net loss of $143.4 million. While revenue growth is strong, profitability remains a concern.
Analysts have lowered price targets significantly, with the range now between $11 and $24. Despite the downgrades, most analysts maintain Buy or Overweight ratings, citing strong adoption and utilization metrics. However, the recent earnings miss and guidance cut have dampened sentiment.
